We use cookies to provide you with a better experience. By continuing to browse the site you are agreeing to our use of cookies in accordance with our Cookie Policy.
Accept
Home » EC Approves Teva-Allergan Merger Under Conditions of Divestments
EC Approves Teva-Allergan Merger Under Conditions of Divestments
European regulators have signed off on Teva Pharmaceutical Industries’ planned $40.5 billion purchase of Allergan’s generics unit, provided the company sells off numerous overlapping product areas to address anti-competitive concerns.
To View This Article:
Login
Subscribe To International Pharmaceutical Regulatory Monitor